Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000102909-25-000255·Monte Rosa Therapeutics, Inc.
Schedule 13G ownership disclosure
Monte Rosa Therapeutics Inc
Common Stock · CUSIP: 61225M102
Event date: 2025-09-30
- Filing-level shares
- 2,988,953
- Percent of class
- 4.83%
- The Vanguard Group
Shares: 2,988,953 · Class: 4.83%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000102909-25-000255
- Form type
- SCHEDULE 13G/A
- Filer
- Monte Rosa Therapeutics, Inc.
- CIK
- CIK 1826457
- Filed
- Oct 31, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership